3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
1
Carcinoma in Situ
1
Interventions
Mitomycin
11
Gemcitabine
7
BCG Vaccine
4
Imiquimod
2
Administration, Intravesical
2
viscum album peptide
1
pemigatinib
1
pembrolizumab
1
erdafitinib
1
dodecyl maltoside
1
Water
1
VPM1002 recombinant BCG vaccine
1
VB4-845
1
Therapeutics
1
Photochemotherapy
1
Neoadjuvant Therapy
1
Interferon-alpha
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Ethacrynic Acid
1
Epirubicin
1
Educational Status
1
Doxorubicin
1
Docetaxel
1
Dihematoporphyrin Ether
1
Cystoscopy
1
Celecoxib
1
BCG Connaught
1
5-aminolevulinic acid hexyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-Muscle Invasive Bladder Neoplasms
×
dodecyl maltoside
×
Clear all
NCT04387461
2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2
Completed
35 enrolled